concomitant medication

Abstract We evaluated adverse drug events (ADE) by chart review in a random national sample of 428 Veterans with COVID-19 who received tocilizumab (n=173/428). ADEs (median time=5 days) occurred in 51/173 (29%) and included hepatoxicity (n=29) and infection (n=13). Concomitant medication discontinuation occurred in 22% of ADE patients; mortality was 39%.

Download Full-text

Effects of eplerenone on resistance to antihypertensive medication in patients with primary or secondary hyperaldosteronism

Journal of Translational Internal Medicine ◽

10.1515/jtim-2017-0020 ◽

2017 ◽

Vol 5 (2) ◽

pp. 93-99 ◽

Cited By ~ 1

Author(s):

J. David Spence ◽

Chrysi Bogiatzi ◽

Mariya Kuk ◽

George K. Dresser ◽

Daniel G. Hackam

Keyword(s):

Blood Pressure ◽

Resistant Hypertension ◽

Concomitant Medication ◽

Antihypertensive Medication ◽

Pressure Control ◽

Blinded Study ◽

History Of ◽

Secondary Hyperaldosteronism ◽

One Year ◽

Resistance Score

Abstract Background and Objectives Resistant hypertension is an important problem; nearly half of diagnosed hypertensives are not controlled to target blood pressure levels, and approximately 90% of strokes occur among patients with resistant hypertension. Primary aldosteronism accounts for approximately 20% of resistant hypertension, but the role of secondary hyperaldosteronism in resistant hypertension is seldom considered. We assessed the effects of eplerenone in patients with hypertension and either primary or secondary hyperaldosteronism. Methods Patients with a history of resistant hypertension and a supine plasma aldosterone level ≥ 360 pmol/L were randomized to eplerenone versus placebo in a fully blinded study for one year. A medication intensity score was developed to assess the resistance of hypertension to medication (blood pressure × medication intensity). We assessed the effects of eplerenone on blood pressure and on resistance to concomitant medication. Results Final results were available in 37 patients (19 on eplerenone and 18 on placebo). Resistance to medication, as assessed by the intensity of concomitant medication required to maintain blood pressure control, was markedly reduced by eplerenone: medication intensity scores declined by –0.50 ± 1.04 (SD) on placebo versus –2.11 ± 1.45 with eplerenone (P = 0.0001), the Systolic Resistance Score declined by –80.00 ± 122.93 on placebo versus –334.05 ± 21.73 on eplerenone (P = 0.0001), and the Diastolic Resistance Score increased by 1.28 ± 31.65 on placebo and declined by –40.74 ± 57.08 on eplerenone (P = 0.009). Conclusions Eplerenone significantly reduced resistance to concomitant antihypertensive medication in both primary and secondary hyperaldosteronism.

Download Full-text

Concomitant Medication Use Completion Status

10.32388/7i7vbt ◽

2020 ◽

Author(s):

Keyword(s):

Concomitant Medication ◽

Medication Use ◽

Completion Status

Download Full-text

Concomitant Medication Start Time

10.32388/dw3xnc ◽

2020 ◽

Author(s):

Keyword(s):

Concomitant Medication ◽

Start Time

Download Full-text

A drug safety surveillance study of a ciprofloxacin / dexamethasone ophthalmic fixed combination in Peruvian population

10.20944/preprints202011.0625.v1 ◽

2020 ◽

Author(s):

Homero Contreras-Salinas ◽

Leopoldo Martín Baiza-Durán ◽

Mariana Barajas-Hernández ◽

Alan Omar Vázquez-Álvarez ◽

Lourdes Yolotzin Rodríguez-Herrera

Keyword(s):

Drug Safety ◽

Concomitant Medication ◽

Fixed Combination ◽

Real Life ◽

Prescribing Patterns ◽

Surveillance Study ◽

Phone Calls ◽

Safety Surveillance ◽

Drug Safety Surveillance ◽

Post Marketing

(1) Background: drugs provide a significant benefit; however, their use implies an intrinsic potential danger, with the possibility to cause unwanted effects. These effects are known as adverse drug reactions (ADRs). Post-marketing drug safety surveillance detects unknown risks that have not been identified in clinical trials and it is necessary to monitor marketed medications under real-life practice. Due to the scarce information about fixed combination of ciprofloxacin 0.3% / dexamethasone 0.1% (SDO), we performed a drug safety surveillance study. (2) Methods: A prospective non-controlled drug safety surveillance study was conducted in Peruvian population. A total of 236 patients prescribed SDO were included derivates from 12 sites. Patients' standardized information was collected through two phone calls, including demographics, medical history, prescribing patterns of SDO, concomitant medication, and ADRs in detail. The ADRs were classified by causality and severity, followed by outcome measures to identify new risk. (3) Results: 236 patients prescribed with SDO participated in the study and 220 were included. A total of 82 ADRs/220 patients were reported after the use of SDO, presenting a ratio 0.37 ADR/patient. The most frequent ADR with SDO administration was eye irritation (30%). The totality of the ADR was classified as non-serious, and the 97.5% (n=80) was classified as mild and 2.5% as moderate (n=2). No cases under the severe category were identified. (4) Conclusion: No new risks were found in the population where this study was conducted.

Download Full-text